HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics (NASDAQ:VYGR)

Key Points

• HC Wainwright has reiterated a Buy rating for Voyager Therapeutics (NASDAQ:VYGR) with a target price of $30.00.
• Despite the positive outlook from HC Wainwright, Wedbush has lowered its target price for the stock from $9.00 to $8.00, with an "outperform" rating.
• Voyager Therapeutics is currently trading at $4.18 and reported a quarterly EPS of ($0.57), missing estimates.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

Separately, Wedbush dropped their target price on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has an average rating of "Buy" and an average target price of $13.25.

Voyager Therapeutics Trading Down 4.6%

Voyager Therapeutics stock opened at $4.18 on Monday. The business's fifty day simple moving average is $3.47 and its two-hundred day simple moving average is $3.41. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $8.27. The company has a market capitalization of $231.86 million, a price-to-earnings ratio of -2.26 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.The company had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million. On average, equities research analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Vestal Point Capital LP increased its position in Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock worth $6,974,000 after buying an additional 740,000 shares in the last quarter. AQR Capital Management LLC increased its position in Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after buying an additional 317,927 shares in the last quarter. Acadian Asset Management LLC increased its position in Voyager Therapeutics by 863.3% in the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after buying an additional 206,758 shares in the last quarter. Nuveen LLC purchased a new stake in Voyager Therapeutics in the first quarter worth about $368,000. Finally, Hsbc Holdings PLC increased its position in Voyager Therapeutics by 118.5% in the second quarter. Hsbc Holdings PLC now owns 148,377 shares of the company's stock worth $440,000 after buying an additional 80,474 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.